BRISTOL-MYERS SQUIBB COMPANY Unrealized Gain (Loss) on Investments
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Unrealized Gain (Loss) on Investments of $49.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnInvestments · last filed 2026-07-30
- BRISTOL-MYERS SQUIBB COMPANY unrealized gain (loss) on investments for the quarter ending 2026-06-30 was $49.00M, a 716.67% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY unrealized gain (loss) on investments for the quarter ending 2026-03-31 was $29.00M.
- BRISTOL-MYERS SQUIBB COMPANY unrealized gain (loss) on investments for the quarter ending 2025-12-31 was $116.00M.
- BRISTOL-MYERS SQUIBB COMPANY unrealized gain (loss) on investments for the quarter ending 2025-09-30 was $166.00M, a 453.33% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY unrealized gain (loss) on investments for fiscal 2025 was $287.00M.
- BRISTOL-MYERS SQUIBB COMPANY unrealized gain (loss) on investments for fiscal 2024 was -$9.00M.
- BRISTOL-MYERS SQUIBB COMPANY unrealized gain (loss) on investments for fiscal 2023 was -$120.00M.
- BRISTOL-MYERS SQUIBB COMPANY unrealized gain (loss) on investments for fiscal 2022 was -$779.00M.
| Period end | Unrealized Gain (Loss) on Investments 3 month | Unrealized Gain (Loss) on Investments 3 month as first filed | Unrealized Gain (Loss) on Investments 6 month | Unrealized Gain (Loss) on Investments 6 month as first filed | Unrealized Gain (Loss) on Investments 9 month | Unrealized Gain (Loss) on Investments 9 month as first filed | Unrealized Gain (Loss) on Investments 12 month | Unrealized Gain (Loss) on Investments 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $49.00M 10-Q · filed 2026-07-30 | $78.00M 10-Q · filed 2026-07-30 | $194.00M derived: sum of 3 quarters · filed 2026-07-30 | $360.00M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2026-03-31 | $29.00M 10-Q · filed 2026-04-30 | $145.00M derived: sum of 2 quarters · filed 2026-04-30 | $311.00M derived: sum of 3 quarters · filed 2026-04-30 | $317.00M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-12-31 | $116.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $282.00M derived: sum of 2 quarters · filed 2026-02-11 | $288.00M derived: sum of 3 quarters · filed 2026-07-30 | $287.00M 10-K · filed 2026-02-11 | ||||
| 2025-09-30 | $166.00M 10-Q · filed 2025-10-30 | $172.00M derived: sum of 2 quarters · filed 2026-07-30 | $171.00M 10-Q · filed 2025-10-30 | $9.00M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-06-30 | $6.00M 10-Q · filed 2026-07-30 | $4.00M 10-Q · filed 2026-07-30 | -$157.00M derived: sum of 3 quarters · filed 2026-07-30 | -$127.00M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-03-31 | -$1.00M 10-Q · filed 2026-04-30 | -$163.00M derived: sum of 2 quarters · filed 2026-04-30 | -$133.00M derived: sum of 3 quarters · filed 2026-04-30 | -$97.00M derived: sum of 4 quarters · filed 2026-04-30 | ||||
| 2024-12-31 | -$162.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$132.00M derived: sum of 2 quarters · filed 2026-02-11 | -$96.00M derived: sum of 3 quarters · filed 2026-02-11 | -$9.00M 10-K · filed 2026-02-11 | ||||
| 2024-09-30 | $30.00M 10-Q · filed 2025-10-30 | $66.00M derived: sum of 2 quarters · filed 2025-10-30 | $153.00M 10-Q · filed 2025-10-30 | $235.00M derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2024-06-30 | $36.00M 10-Q · filed 2025-07-31 | $123.00M 10-Q · filed 2025-07-31 | $205.00M derived: sum of 3 quarters · filed 2026-02-11 | $104.00M derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2024-03-31 | $88.00M 10-Q · filed 2025-04-24 | $169.00M derived: sum of 2 quarters · filed 2026-02-11 | $68.00M derived: sum of 3 quarters · filed 2026-02-11 | $10.00M derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2023-12-31 | $81.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$20.00M derived: sum of 2 quarters · filed 2026-02-11 | -$78.00M derived: sum of 3 quarters · filed 2026-02-11 | -$120.00M 10-K · filed 2026-02-11 | ||||
| 2023-09-30 | -$101.00M 10-Q · filed 2024-10-31 | -$159.00M derived: sum of 2 quarters · filed 2024-10-31 | -$201.00M 10-Q · filed 2024-10-31 | -$134.00M derived: sum of 4 quarters · filed 2025-02-12 | ||||
| 2023-06-30 | -$58.00M 10-Q · filed 2024-07-26 | -$200.00M 10-Q · filed 2024-07-26 | -$33.00M derived: sum of 3 quarters · filed 2025-02-12 | -$109.00M derived: sum of 4 quarters · filed 2025-02-12 | ||||
| 2023-03-31 | -$140.00M 10-Q · filed 2024-04-25 | $25.00M derived: sum of 2 quarters · filed 2025-02-12 | -$51.00M derived: sum of 3 quarters · filed 2025-02-12 | -$321.00M derived: sum of 4 quarters · filed 2025-02-12 | ||||
| 2022-12-31 | $165.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $89.00M derived: sum of 2 quarters · filed 2025-02-12 | -$181.00M derived: sum of 3 quarters · filed 2025-02-12 | -$779.00M 10-K · filed 2025-02-12 | ||||
| 2022-09-30 | -$76.00M 10-Q · filed 2023-10-26 | -$346.00M derived: sum of 2 quarters · filed 2023-10-26 | -$944.00M 10-Q · filed 2023-10-26 | -$1.80B derived: sum of 4 quarters · filed 2024-02-13 | ||||
| 2022-06-30 | -$270.00M 10-Q · filed 2023-07-27 | -$868.00M 10-Q · filed 2023-07-27 | -$1.73B derived: sum of 3 quarters · filed 2024-02-13 | -$1.75B derived: sum of 4 quarters · filed 2024-02-13 | ||||
| 2022-03-31 | -$598.00M 10-Q · filed 2023-04-27 | -$1.46B derived: sum of 2 quarters · filed 2024-02-13 | -$1.48B derived: sum of 3 quarters · filed 2024-02-13 | -$1.56B derived: sum of 4 quarters · filed 2024-02-13 | ||||
| 2021-12-31 | -$858.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-13 | -$877.00M derived: sum of 2 quarters · filed 2024-02-13 | -$959.00M derived: sum of 3 quarters · filed 2024-02-13 | -$760.00M 10-K · filed 2024-02-13 | ||||
| 2021-09-30 | -$19.00M 10-Q · filed 2022-10-26 | -$101.00M derived: sum of 2 quarters · filed 2022-10-26 | $98.00M 10-Q · filed 2022-10-26 | $2.00M 10-Q · filed 2021-10-27 | $497.00M derived: sum of 4 quarters · filed 2023-02-14 | |||
| 2021-06-30 | -$82.00M 10-Q · filed 2022-07-27 | $11.00M 10-Q · filed 2021-07-28 | $117.00M 10-Q · filed 2022-07-27 | $353.00M 10-Q · filed 2021-07-28 | $516.00M derived: sum of 3 quarters · filed 2023-02-14 | $686.00M derived: sum of 4 quarters · filed 2023-02-14 | ||
| 2021-03-31 | $199.00M 10-Q · filed 2022-04-29 | $381.00M 10-Q · filed 2021-04-29 | $598.00M derived: sum of 2 quarters · filed 2023-02-14 | $768.00M derived: sum of 3 quarters · filed 2023-02-14 | $1.55B derived: sum of 4 quarters · filed 2023-02-14 | |||
| 2020-12-31 | $399.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | $569.00M derived: sum of 2 quarters · filed 2023-02-14 | $1.35B derived: sum of 3 quarters · filed 2023-02-14 | $976.00M 10-K · filed 2023-02-14 | $1.20B 10-K · filed 2021-02-10 | |||
| 2020-09-30 | $170.00M 10-Q · filed 2021-10-27 | $948.00M derived: sum of 2 quarters · filed 2021-10-27 | $577.00M 10-Q · filed 2021-10-27 | |||||
| 2020-06-30 | $778.00M 10-Q · filed 2021-07-28 | $550.00M 10-Q · filed 2021-07-28 | ||||||
| 2020-03-31 | -$228.00M 10-Q · filed 2021-04-29 | |||||||
| 2019-12-31 | $156.00M 10-K · filed 2022-02-09 | |||||||
| 2018-12-31 | $537.00M 10-K · filed 2021-02-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |